Drug
Intismeran Autogene
Intismeran Autogene: highest development phase Phase 3, developed by Merck. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Intismeran autogene NCT06623422 | Phase 3 | Carcinoma, Non-Small-Cell Lung |
| Intismeran autogene NCT06961006 | Phase 2 | Malignant Melanoma |
Latest
No recent events.
Follow Intismeran Autogene on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.